Investor Newsletter

Issue 12 2022

MicroPort®

6 Endovastec™ Products Approved for Marketing in Belarus

Recently, six products independently developed by Endovastec™ (SSE: 688016) have been approved by the Ministry of Health of Belarus for registration. This marks the first time that Endovastec™ has obtained product approvals in Belarus, laying a solid foundation for the company to enter the market.

Currently, the Endovastec™ products approved for marketing in Belarus include the Castor® Branched Aortic Stent-Graft and Delivery System, Hercules® Low Profile Straight Tube-Type Stent-Graft and Delivery System, Minos® Abdominal Aortic Stent-Graft and Delivery System, Hercules® Bifurcated Stent-Graft and Delivery System, CRONUS® Intraoperative Stent System (CRONUS®), and Hercules® Balloon Dilatation Catheter. These are the six core Endovastec™ products in the field of aortic therapy, encompassing thoracic endovascular aortic repair, abdominal aortic endoluminal therapy, and surgeries.

Among domestic brands of aortic products, Endovastec™ has enjoyed the largest market share in China for years. The approval of the six aortic products in Belarus is also a strategic globalization move for Endovastec™ to enter emerging markets abroad while continuing its penetration in the domestic mature market. This initiative lays the foundation for the company's future expansion into the Eastern European market as well as accelerated coverage of the global market. In the future, Endovastec™ will continue its effort to introduce more high-quality and high-end innovative medical devices to global markets, bringing better medical solutions for blood circulation diseases to patients and physicians worldwide.



MicroPort

MicroPort® MedBot® SkyWalker™ Orthopedic Surgical Robot Obtains CE Marking in EU

MicroPort® OrthoBot, a fully-owned subsidiary of MicroPort® MedBot® (2252.HK) has recently obtained CE marking in the European Union (EU) for its independently developed SkyWalker™ Orthopedic Surgical Robot (SkyWalker™), becoming the first orthopedic surgical robot in China to receive this certification. SkyWalker™ obtained marketing approval from the Chinese National Medical Products Administration (NMPA) and was certified by the U.S. Food and Drug Administration (FDA) in April and July 2022, respectively. It is the first and only surgical robot developed by a Chinese company to obtain marketing approval and certification from the NMPA, FDA and CE.

The CE marking represents recognition from the EU medical device regulators and confirms that the effectiveness and safety of SkyWalker™ are comparable to its international counterparts. It also signifies that MicroPort® OrthoBot has completed its preliminary preparation to enter key markets around the world, which is of great significance for MicroPort® MedBot® in realizing its vision of "building a medical robotics total solution innovation platform with global presence".

According to Dr. Yangbin Chen, General Manager of MicroPort® OrthoBot: "For MicroPort® SkyWalker™ Orthopedic Surgical Robot, the CE marking is a manifestation of MicroPort® OrthoBot's core technology and its rapid product iteration capability. It is another important breakthrough after obtaining FDA certification. SkyWalker™ can provide global patients with professional, safe and efficient digital and integrated orthopedic surgical solutions."

Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort® MedBot®, stated: "SkyWalker™ Orthopedic Surgical Robot has been approved and certified in China, the United States and the European Union one after another within one year, which demonstrates the strong technical strength and product performance of Chinese orthopedic surgical robots. The certification in overseas markets and smooth market entry will help MicroPort® MedBot® accelerate its globalization strategy, help more patients globally, and realize our aspiration from day one to eliminate difficult surgeries in the world."

MicroPort

Investor Newsletter

Issue 12 2022

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com